| Line Item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Statement [line items] | |||||||||
| Net sales from continuing operations | |||||||||
| Other revenues | |||||||||
| Cost of goods sold | |||||||||
| Gross profit from continuing operations | |||||||||
| Selling, general and administration | |||||||||
| Research and development | |||||||||
| Other income | |||||||||
| Other expense | |||||||||
| Operating income from continuing operations | |||||||||
| Loss from associated companies | |||||||||
| Interest expense | |||||||||
| Other financial income and expense | |||||||||
| Income before taxes from continuing operations | |||||||||
| Income taxes | |||||||||
| Net income from continuing operations | |||||||||
| Net income from discontinued operations before gain on distribution | — | ||||||||
| Net income from discontinued operations | — | ||||||||
| Net income | |||||||||
| Attributable to | |||||||||
| Shareholders of Novartis AG | |||||||||
| Non-controlling interests |